Sonoma Pharmaceuticals (SNOA) Reaches $7.33 After 3.00% Up Move, Teligent (TLGT) Sellers Decreased By 2.98% Their Shorts

June 2, 2017 - By marketbeat

The stock of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) is a huge mover today! About 50,283 shares traded or 230.74% up from the average. Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has risen 35.93% since June 2, 2016 and is uptrending. It has outperformed by 19.23% the S&P500.The move comes after 6 months positive chart setup for the $30.40M company. It was reported on Jun, 2 by Barchart.com. We have $7.55 PT which if reached, will make NASDAQ:SNOA worth $912,000 more.

Teligent Incorporated (NASDAQ:TLGT) had a decrease of 2.98% in short interest. TLGT’s SI was 7.32 million shares in June as released by FINRA. Its down 2.98% from 7.55 million shares previously. With 210,500 avg volume, 35 days are for Teligent Incorporated (NASDAQ:TLGT)’s short sellers to cover TLGT’s short positions. The SI to Teligent Incorporated’s float is 17.03%. About 219,687 shares traded. Teligent Inc (NASDAQ:TLGT) has risen 64.58% since June 2, 2016 and is uptrending. It has outperformed by 47.88% the S&P500.

Analysts await Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) to report earnings on June, 15.

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical firm that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company has market cap of $30.40 million. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. It currently has negative earnings. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue.

Teligent, Inc. is a specialty generic pharmaceutical company. The company has market cap of $472.61 million. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. It currently has negative earnings. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.